A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

October 25, 2023

Study Completion Date

April 5, 2024

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

CC-90009

Injection

DRUG

Venetoclax

Tablet

DRUG

Azacitidine

Injection

DRUG

Gilteritinib

Tablet

Trial Locations (14)

5530

Local Institution - UNK3, Yvoir

13273

Local Institution - 402, Marseille

31059

Local Institution - 404, Toulouse

33604

Local Institution - 401, Pessac

63110

Local Institution - 101, St Louis

94143-0324

Local Institution - 104, San Francisco

06510

Local Institution - 107, New Haven

02115

Local Institution - 103, Boston

07601

Local Institution - 108, Hackensack

77030-4009

Local Institution - 105, Houston

98109-1024

Local Institution - 102, Seattle

T6G 2R7

Local Institution - 202, Edmonton

M5G 2M9

Local Institution - 201, Toronto

OX3 9DU

Local Institution - 301, Oxford

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Celgene

INDUSTRY